Loading clinical trials...
Loading clinical trials...
Phase II Randomized Trial of the Polo-like Kinase 1 Inhibitor BI 6727 Monotherapy Versus Investigator´s Choice Chemotherapy in Ovarian Cancer Patients Resistant or Refractory to Platinum-based Cytotoxic Therapy
Conditions
Interventions
Paclitaxel
Gemcitabine
+3 more
Locations
31
Belgium
1230.18.32003 Boehringer Ingelheim Investigational Site
Brussels, Belgium
1230.18.32004 Boehringer Ingelheim Investigational Site
Edegem, Belgium
1230.18.32002 Boehringer Ingelheim Investigational Site
Ghent, Belgium
1230.18.32001 Boehringer Ingelheim Investigational Site
Leuven, Belgium
1230.18.3321A Boehringer Ingelheim Investigational Site
Angers, France
1230.18.3307A Boehringer Ingelheim Investigational Site
Bordeaux, France
Start Date
April 1, 2010
Primary Completion Date
June 1, 2014
Completion Date
June 1, 2014
Last Updated
August 13, 2015
NCT07213804
NCT06051695
NCT06885697
NCT07035587
NCT01789229
NCT02869568
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions